LINCS gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1

  • Authors:
    • Sai Hu
    • Dafei Xie
    • Pingkun Zhou
    • Xiaodan Liu
    • Xiaoyao Yin
    • Bo Huang
    • Hua Guan
  • View Affiliations

  • Published online on: March 2, 2021     https://doi.org/10.3892/ijmm.2021.4905
  • Article Number: 72
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Radioresistance is the predominant cause for radiotherapy failure and disease progression, resulting in increased breast cancer‑associated mortality. Using gene expression signature analysis of the Library of Integrated Network‑Based Cellular Signatures (LINCS) and Gene Expression Omnibus (GEO), the aim of the present study was to systematically identify potential candidate radiosensitizers from known drugs. The similarity of integrated gene expression signatures between irradiated eukaryotic translation initiation factor 4 γ 1 (eIF4G1)‑silenced breast cancer cells and known drugs was measured using enrichment scores (ES). Drugs with positive ES were selected as potential radiosensitizers. The radiosensitizing effects of the candidate drugs were analyzed in breast cancer cell lines (MCF‑7, MX‑1 and MDA‑MB‑231) using CCK‑8 and colony formation assays following exposure to ionizing radiation. Cell apoptosis was measured using flow cytometry. The expression levels of eIF4G1 and DNA damage response (DDR) proteins were analyzed by western blotting. Bosutinib was identified as a promising radiosensitizer, as its administration markedly reduced the dosage required both for the drug and for ionizing radiation, which may be associated with fewer treatment‑associated adverse reactions. Moreover, combined treatment of ionizing radiation and bosutinib significantly increased cell killing in all three cell lines, compared with ionizing radiation or bosutinib alone. Among the three cell lines, MX‑1 cells were identified as the most sensitive to both ionizing radiation and bosutinib. Bosutinib markedly downregulated the expression of eIF4G1 in a dose‑dependent manner and also reduced the expression of DDR proteins (including ATM, XRCC4, ATRIP, and GADD45A). Moreover, eIF4G1 was identified as a key target of bosutinib that may regulate DNA damage induced by ionizing radiation. Thus, bosutinib may serve as a potential candidate radiosensitizer for breast cancer therapy.
View Figures
View References

Related Articles

Journal Cover

May-2021
Volume 47 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hu S, Xie D, Zhou P, Liu X, Yin X, Huang B and Guan H: <em>LINCS</em> gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1. Int J Mol Med 47: 72, 2021
APA
Hu, S., Xie, D., Zhou, P., Liu, X., Yin, X., Huang, B., & Guan, H. (2021). <em>LINCS</em> gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1. International Journal of Molecular Medicine, 47, 72. https://doi.org/10.3892/ijmm.2021.4905
MLA
Hu, S., Xie, D., Zhou, P., Liu, X., Yin, X., Huang, B., Guan, H."<em>LINCS</em> gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1". International Journal of Molecular Medicine 47.5 (2021): 72.
Chicago
Hu, S., Xie, D., Zhou, P., Liu, X., Yin, X., Huang, B., Guan, H."<em>LINCS</em> gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1". International Journal of Molecular Medicine 47, no. 5 (2021): 72. https://doi.org/10.3892/ijmm.2021.4905